tiprankstipranks
Cogent Biosciences, Inc. (COGT)
NASDAQ:COGT
US Market
COGT
Cogent Biosciences
RESEARCH TOOLSreports

Cogent Biosciences (COGT) Stock News & Sentiment

719 Followers
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
Premium
Ratings
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
8d ago
COGT
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
Premium
Company Announcements
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
14d ago
COGT
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
Premium
Ratings
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
2M ago
COGT
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
Premium
Company Announcements
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
2M ago
COGT
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
Premium
Ratings
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
2M ago
COGT
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
Premium
Company Announcements
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
3M ago
COGT
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
Premium
Ratings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
3M ago
COGT
More COGT News >

COGT News on the Web

Why Cogent Biosciences Shares Are Under Pressure
TipRanks News
Bullish
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT)
TipRanks News
Bullish
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
TipRanks News
Bullish
Cogent Submits NDA For Bezuclastinib In GIS Tumours After Non-AdvSM; Eyes NDA For AdvSM In H1,2026
rttnews
Bullish
Fairmount Funds Management LLC Increases Stake in Apogee Therapeutics Inc
GuruFocus News
Neutral
Cogent Biosciences submits bezuclastinib new drug application to the FDA
TipRanks News
Bullish
Bezuclastinib Shows 50% Risk Reduction in GIST: Cogent Biosciences Submits NDA After Landmark Phase 3 Results
Market Chameleon
Neutral

News Score - Last 7 Days

Neutral
COGT
Sector Average
Media Buzz
This Week1 articles
Weekly Average5.5 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is COGT’s Media Buzz Sentiment?
1 articles about COGT were published this week. In an average week, 5.5 articles are published.
    What is COGT’s weekly average amount of articles?
    In an average week, 5.5 articles about COGT are published.
      What is COGT’s News Sentiment?
      100% of articles about COGT were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        NBIXNeurocrine
        STAAStaar Surgical
        AORTArtivion
        OWLTOwlet
        HUMHumana
        Showing the stocks with the most bullish news sentiment over the past week